Jefferies raises Viatris stock price target to $22 on guidance lift
Jefferies raised its price target for Viatris (VTRS) to $22 from $20, citing raised guidance despite a Q3 revenue miss. The stock is up 94% over the past year. Viatris reported adjusted EPS of $0.71, beating estimates, and raised full-year guidance for revenue, EBITDA, and EPS growth. China performance is slowing, but the estrogen patch is a growth driver. Supply shortages in Europe and emerging markets are expected to impact Q4 results.
How this was made
The 30-second read
Why it matters
The analyst's price target increase provides a fresh catalyst that could drive short-term buying interest.
Market read
The new target may attract momentum traders and influence sector sentiment.
What to watch
Supply shortages in Europe could pressure margins in Q4 despite the target increase.
Background
Jefferies' analyst note follows Viatris' Q3 earnings release, which missed revenue expectations but beat EBITDA and raised guidance.
Ticker impact
Jefferies raised its price target on Viatris Inc. (VTRS) to $22 from $20 after the company reported Q3 results and lifted its guidance.
likely upward pressure as investors price in the higher target and improved guidance
Analyst upgrade with a concrete price target change typically moves the stock in the direction of the new target, especially after a guidance lift.
Market effects
Positive for the generic pharmaceuticals sector as the upgrade may lift peers.
Minimal regional effect; primarily U.S. market focused.
Limited global relevance beyond Viatris and its sector.
Counterpoint
The target raise may be premature if the revenue shortfall persists, suggesting caution.
Key entities
- companyViatris Inc.
U.S.-listed pharmaceutical company (NASDAQ:VTRS).
- analyst_firmJefferies
Equity research firm that issued the price target raise.
